Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
Public ClinicalTrials.gov record NCT03485911. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema
Study identification
- NCT ID
- NCT03485911
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- BioCryst Pharmaceuticals
- Industry
- Enrollment
- 121 participants
Conditions and interventions
Conditions
Interventions
- BCX7353 capsules Drug
- Placebo oral capsule Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 5, 2018
- Primary completion
- Apr 9, 2019
- Completion
- Apr 5, 2022
- Last update posted
- Jun 25, 2023
2018 – 2022
United States locations
- U.S. sites
- 27
- U.S. states
- 19
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Study center | Birmingham | Alabama | 35209 | — |
| Study center | Scottsdale | Arizona | 85251 | — |
| Study center | Little Rock | Arkansas | 72205 | — |
| Study Center | San Diego | California | 92122 | — |
| Study center | Santa Monica | California | 90404 | — |
| Study Center | Walnut Creek | California | 94598 | — |
| Study center | Colorado Springs | Colorado | 80907 | — |
| Study Center | Tampa | Florida | 33613 | — |
| Study center | Chevy Chase | Maryland | 20815 | — |
| Study Center | Boston | Massachusetts | 02114 | — |
| Study Center | Ann Arbor | Michigan | 48106 | — |
| Study center | Plymouth | Minnesota | 55446 | — |
| Study Center | St Louis | Missouri | 63141 | — |
| Study center | Belleville | New Jersey | 07109 | — |
| Study Center | Fair Lawn | New Jersey | 07410 | — |
| Study center | Piscataway | New Jersey | 08854 | — |
| Study Center | New York | New York | 10029 | — |
| Study Site | Charlotte | North Carolina | 28277 | — |
| Study Center | Durham | North Carolina | 27705 | — |
| Study Center | Cincinnati | Ohio | 45231 | — |
| Study center | Columbus | Ohio | 43235 | — |
| Study center | Clackamas | Oregon | 97015 | — |
| Study Center | Hershey | Pennsylvania | 17033 | — |
| Study center | Austin | Texas | 78731 | — |
| Study center | Dallas | Texas | 75231 | — |
| Study Center | San Antonio | Texas | 78229 | — |
| Study Center | Spokane | Washington | 99202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03485911, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 25, 2023 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03485911 live on ClinicalTrials.gov.